Is Tesla Stock Overvalued or a Buy for the Next Decade?
Shares of EV major Tesla (NASDAQ:TSLA) have experienced extreme volatility…
Sell
46
MTNB Quote, Financials, Valuation and Earnings
Last price:
$0.85
Seasonality move
:
-19.53%
Day range:
$0.77 - $0.98
52-week range:
$0.47 - $9.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.94x
P/B ratio:
0.65x
Volume:
187.8K
Avg. volume:
115.7K
1-year change:
-90.36%
Market cap:
$4.1M
Revenue:
$1.1M
EPS (TTM):
-$3.86
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MTNB
Matinas BioPharma Holdings
|
-- | -$0.78 | -100% | -45.83% | -- |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$0.28 | -100% | -7.24% | $5.00 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
Nanoviricides
|
-- | -$0.20 | -- | -26.67% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
TOVX
Theriva Biologics
|
-- | -$1.56 | -- | -95.63% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MTNB
Matinas BioPharma Holdings
|
$0.80 | -- | $4.1M | -- | $0.00 | 0% | 0.94x |
|
ATNM
Actinium Pharmaceuticals
|
$1.60 | $5.00 | $49.9M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.57 | $0.85 | $3.3M | -- | $0.00 | 0% | 0.16x |
|
NNVC
Nanoviricides
|
$1.71 | -- | $27.5M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics
|
$0.19 | $1.00 | $4.1M | -- | $0.00 | 0% | 1.84x |
|
TOVX
Theriva Biologics
|
$0.43 | $7.00 | $3.5M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MTNB
Matinas BioPharma Holdings
|
-- | 1.451 | -- | -- |
|
ATNM
Actinium Pharmaceuticals
|
-- | -3.541 | -- | 9.03x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.186 | 1.51% | 0.75x |
|
NNVC
Nanoviricides
|
-- | 2.080 | -- | -- |
|
OGEN
Oragenics
|
-- | 3.254 | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -2.512 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MTNB
Matinas BioPharma Holdings
|
-- | -$1.9M | -- | -- | -- | -$2M |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$16.6M | -95.08% | -95.08% | -12769.14% | -$7.6M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$2.7M | -334.47% | -461.38% | -44% | -$1.3M |
|
NNVC
Nanoviricides
|
-- | -$2.2M | -- | -- | -- | -$2M |
|
OGEN
Oragenics
|
-- | -$2M | -- | -- | -- | -$2.1M |
|
TOVX
Theriva Biologics
|
-- | -$4.4M | -- | -- | -- | -$4.8M |
Matinas BioPharma Holdings vs. Competitors
-
Which has Higher Returns MTNB or ATNM?
Actinium Pharmaceuticals has a net margin of -- compared to Matinas BioPharma Holdings's net margin of -11511.11%. Matinas BioPharma Holdings's return on equity of -- beat Actinium Pharmaceuticals's return on equity of -95.08%.
Company Gross Margin Earnings Per Share Invested Capital MTNBMatinas BioPharma Holdings-- -$0.33 -- ATNMActinium Pharmaceuticals-- -$0.51 $36.4M -
What do Analysts Say About MTNB or ATNM?
Matinas BioPharma Holdings has a consensus price target of --, signalling upside risk potential of 3650%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 212.5%. Given that Matinas BioPharma Holdings has higher upside potential than Actinium Pharmaceuticals, analysts believe Matinas BioPharma Holdings is more attractive than Actinium Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings MTNBMatinas BioPharma Holdings0 2 0 ATNMActinium Pharmaceuticals2 1 0 -
Is MTNB or ATNM More Risky?
Matinas BioPharma Holdings has a beta of 1.193, which suggesting that the stock is 19.261% more volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.236, suggesting its less volatile than the S&P 500 by 123.637%.
-
Which is a Better Dividend Stock MTNB or ATNM?
Matinas BioPharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Matinas BioPharma Holdings pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MTNB or ATNM?
Matinas BioPharma Holdings quarterly revenues are --, which are smaller than Actinium Pharmaceuticals quarterly revenues of $81K. Matinas BioPharma Holdings's net income of -$1.7M is higher than Actinium Pharmaceuticals's net income of -$15.9M. Notably, Matinas BioPharma Holdings's price-to-earnings ratio is -- while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Matinas BioPharma Holdings is 0.94x versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MTNBMatinas BioPharma Holdings0.94x -- -- -$1.7M ATNMActinium Pharmaceuticals-- -- $81K -$15.9M
-
Which has Higher Returns MTNB or NBY?
NovaBay Pharmaceuticals has a net margin of -- compared to Matinas BioPharma Holdings's net margin of -49.65%. Matinas BioPharma Holdings's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital MTNBMatinas BioPharma Holdings-- -$0.33 -- NBYNovaBay Pharmaceuticals65.26% $1.42 $1.1M -
What do Analysts Say About MTNB or NBY?
Matinas BioPharma Holdings has a consensus price target of --, signalling upside risk potential of 3650%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 50.23%. Given that Matinas BioPharma Holdings has higher upside potential than NovaBay Pharmaceuticals, analysts believe Matinas BioPharma Holdings is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings MTNBMatinas BioPharma Holdings0 2 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is MTNB or NBY More Risky?
Matinas BioPharma Holdings has a beta of 1.193, which suggesting that the stock is 19.261% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.
-
Which is a Better Dividend Stock MTNB or NBY?
Matinas BioPharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Matinas BioPharma Holdings pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MTNB or NBY?
Matinas BioPharma Holdings quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Matinas BioPharma Holdings's net income of -$1.7M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Matinas BioPharma Holdings's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Matinas BioPharma Holdings is 0.94x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MTNBMatinas BioPharma Holdings0.94x -- -- -$1.7M NBYNovaBay Pharmaceuticals0.16x -- $2.4M $7.7M
-
Which has Higher Returns MTNB or NNVC?
Nanoviricides has a net margin of -- compared to Matinas BioPharma Holdings's net margin of --. Matinas BioPharma Holdings's return on equity of -- beat Nanoviricides's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MTNBMatinas BioPharma Holdings-- -$0.33 -- NNVCNanoviricides-- -$0.14 -- -
What do Analysts Say About MTNB or NNVC?
Matinas BioPharma Holdings has a consensus price target of --, signalling upside risk potential of 3650%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 280.12%. Given that Matinas BioPharma Holdings has higher upside potential than Nanoviricides, analysts believe Matinas BioPharma Holdings is more attractive than Nanoviricides.
Company Buy Ratings Hold Ratings Sell Ratings MTNBMatinas BioPharma Holdings0 2 0 NNVCNanoviricides0 0 0 -
Is MTNB or NNVC More Risky?
Matinas BioPharma Holdings has a beta of 1.193, which suggesting that the stock is 19.261% more volatile than S&P 500. In comparison Nanoviricides has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.32%.
-
Which is a Better Dividend Stock MTNB or NNVC?
Matinas BioPharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Matinas BioPharma Holdings pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MTNB or NNVC?
Matinas BioPharma Holdings quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. Matinas BioPharma Holdings's net income of -$1.7M is higher than Nanoviricides's net income of -$2.2M. Notably, Matinas BioPharma Holdings's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Matinas BioPharma Holdings is 0.94x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MTNBMatinas BioPharma Holdings0.94x -- -- -$1.7M NNVCNanoviricides-- -- -- -$2.2M
-
Which has Higher Returns MTNB or OGEN?
Oragenics has a net margin of -- compared to Matinas BioPharma Holdings's net margin of --. Matinas BioPharma Holdings's return on equity of -- beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MTNBMatinas BioPharma Holdings-- -$0.33 -- OGENOragenics-- -$0.12 -- -
What do Analysts Say About MTNB or OGEN?
Matinas BioPharma Holdings has a consensus price target of --, signalling upside risk potential of 3650%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 420.83%. Given that Matinas BioPharma Holdings has higher upside potential than Oragenics, analysts believe Matinas BioPharma Holdings is more attractive than Oragenics.
Company Buy Ratings Hold Ratings Sell Ratings MTNBMatinas BioPharma Holdings0 2 0 OGENOragenics0 1 0 -
Is MTNB or OGEN More Risky?
Matinas BioPharma Holdings has a beta of 1.193, which suggesting that the stock is 19.261% more volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.
-
Which is a Better Dividend Stock MTNB or OGEN?
Matinas BioPharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Matinas BioPharma Holdings pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MTNB or OGEN?
Matinas BioPharma Holdings quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Matinas BioPharma Holdings's net income of -$1.7M is higher than Oragenics's net income of -$2.2M. Notably, Matinas BioPharma Holdings's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Matinas BioPharma Holdings is 0.94x versus 1.84x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MTNBMatinas BioPharma Holdings0.94x -- -- -$1.7M OGENOragenics1.84x -- -- -$2.2M
-
Which has Higher Returns MTNB or TOVX?
Theriva Biologics has a net margin of -- compared to Matinas BioPharma Holdings's net margin of --. Matinas BioPharma Holdings's return on equity of -- beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MTNBMatinas BioPharma Holdings-- -$0.33 -- TOVXTheriva Biologics-- -$1.55 -- -
What do Analysts Say About MTNB or TOVX?
Matinas BioPharma Holdings has a consensus price target of --, signalling upside risk potential of 3650%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1527.91%. Given that Matinas BioPharma Holdings has higher upside potential than Theriva Biologics, analysts believe Matinas BioPharma Holdings is more attractive than Theriva Biologics.
Company Buy Ratings Hold Ratings Sell Ratings MTNBMatinas BioPharma Holdings0 2 0 TOVXTheriva Biologics1 1 0 -
Is MTNB or TOVX More Risky?
Matinas BioPharma Holdings has a beta of 1.193, which suggesting that the stock is 19.261% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.
-
Which is a Better Dividend Stock MTNB or TOVX?
Matinas BioPharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Matinas BioPharma Holdings pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MTNB or TOVX?
Matinas BioPharma Holdings quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Matinas BioPharma Holdings's net income of -$1.7M is higher than Theriva Biologics's net income of -$4.3M. Notably, Matinas BioPharma Holdings's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Matinas BioPharma Holdings is 0.94x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MTNBMatinas BioPharma Holdings0.94x -- -- -$1.7M TOVXTheriva Biologics0.33x -- -- -$4.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Apple Stock Undervalued or Overvalued?
For many years, Apple (NASDAQ:AAPL) was just about the perfect…
Where Will Palo Alto Networks Stock Be in 5 Years?
You know those companies that just refuse to slow down…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
68
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
58
TNXP alert for May 28
Tonix Pharmaceuticals Holding [TNXP] is up 1.57% over the past day.
Sell
37
ATS alert for May 29
ATS [ATS] is down 1.27% over the past day.
Buy
88
SMR alert for May 28
NuScale Power [SMR] is down 0.37% over the past day.
